Generic Solid Dosage Forms: Products, Markets, Players and Outlook
|出版商||Greystone Research Associates||商品編碼||395940|
|非專利固態劑:產品、市場、企業、展望 Generic Solid Dosage Forms: Products, Markets, Players and Outlook|
|出版日期: 2016年11月18日||內容資訊: 英文||
The generic solid dosage form drug segment is a rapidly evolving and highly unpredictable environment that has been a challenge to decision makers attempting to map strategies for success in this segment. There are 597 distinct APIs for which there is at least one approved generic solid dosage form ANDA. These 597 APIs account for 4,229 approved ANDAs. Including all approved doses, the current universe of generic solid dosage forms consists of 9,687 unique tablet and capsule products. These products are marketed and supplied by more than 800 companies. Competition among the various drug and therapeutic classes is uneven, with the top ten segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets.
Therapeutic Class Analysis
Includes more than eighty drug classes
Analyzes more than three dozen market segments